Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARREST-BP: Nomacopan in Bullous Pemphigoid
2020-005987-67Phase 3Active
- Sponsor
- Akari Therapeutics
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Bullous Pemphigoid (BP) comparing Nomacopan + oral corticosteroid with Placebo + oral corticosteroid (2 arms). Primary endpoint: Complete Disease Remission on minimal oral corticosteroid therapy. Started Jul 2021; status: active.
02
Drugs
nomacopan
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2020-005987-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005987-67.